Targeting the androgen receptor pathway in prostate cancer.
Targeting the androgen receptor pathway in prostate cancer.
复制标题
DOI:
10.1016/j.coph.2008.07.005
复制
发表时间:
2008-08
影响因子:
4
通讯作者:
Scher, Howard I.
中科院分区:
文献类型:
--
作者:
Chen, Yu;Sawyers, Charles L.;Scher, Howard I.
When prostate cancers progress following androgen depletion therapy, there are currently few treatment options with only one, docetaxel, that has been shown to prolong life. Recent work has shown that castration resistant prostate cancers (CRPC) continue to depend on androgen receptor (AR) signaling which is reactivated despite low serum androgen levels. Currently available AR targeted therapy, including GnRH agonists and antiandrogens, cannot completely shut down AR signaling. Several mechanisms that enhance AR signaling in an androgen depleted environment have been elucidated. These include AR mutations that allow activation by low androgen levels or by other endogenous steroids, AR overexpression, increased local intracrine synthesis of androgens, and upregulation of tyrosine kinase pathways. This has led to the development of a number of novel agents targeting AR signaling pathway, including more effective antiandrogens, inhibitors of CYP17, an enzyme required for androgen synthesis, inhibitors of 5α-reductase, inhibitors of HSP90 which protects AR from degradation, inhibitors of histone deacetylases which is required for optimal AR mediated transcription, as well as inhibitors of tyrosine kinase inhibitors. Many of these strategies are currently being tested in clinical trials in CRPC.
登录
查看更多内容
影响因子:
5.7
作者:
Marrocco, Deborah L.;Tilley, Wayne D.;Butler, Lisa M.
通讯作者:
Butler, Lisa M.
DOI:
10.1073/pnas.0700420104
发表时间:
2007-05-15
影响因子:
11.1
作者:
Mahajan, Nupam P.;Liu, Yuanbo;Whang, Young E.
通讯作者:
Whang, Young E.
影响因子:
82.9
作者:
Craft, N;Shostak, Y;Sawyers, CL
通讯作者:
Sawyers, CL
影响因子:
4
作者:
Korkmaz, CG;Fronsdal, K;Saatcioglu, F
通讯作者:
Saatcioglu, F
影响因子:
8.8
作者:
通讯作者:
--